LOGIN  |  REGISTER
Recursion
Chimerix

Emergent BioSolutions to Participate in Upcoming Investor Conferences

May 14, 2025 | Last Trade: US$6.41 0.11 1.75

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of its executive management team will participate in the following investor conferences:

  • RBC Global Healthcare Conference (New York, New York)
    Fireside chat on Tuesday, May 20 at 3:35 pm ET
    Virtual attendees can participate via webcast
  • Goldman Sachs Leveraged Finance Conference, May 29, 2025 (Dana Point, California)
  • Benchmark’s 5th Annual Healthcare House Call Virtual Investor Conference
    Presentation on Thursday, May 29
  • Jefferies Global Healthcare Conference (New York, New York)
    Presentation on Thursday, June 5 at 1:25 pm ET
    Virtual attendees can participate via webcast

A replay of the presentations can be accessed from the Investors page of Emergent’s website.

About Emergent BioSolutions 

At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedInXInstagramApple Podcasts and Spotify. 

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Assal Hellmer
Vice President, Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page